Skip to main content
SpringerLink
Log in

Rosiglitazone's risk: conflicts of interest bias conclusions

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Wang AT, McCoy CP, Murad MH, Montori VM.Association between industry affiliation and position on cardiovascular risk with rosiglitazone: cross sectional systematic review. BMJ 340: Online first [6 pages], 2010. Available from: URL: http://dx.doi.org/10.1136/bmj.c1344

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rosiglitazone's risk: conflicts of interest bias conclusions. React. Wkly. 1294, 4 (2010). https://doi.org/10.2165/00128415-201012940-00012

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128415-201012940-00012

Keywords

Search

Navigation